Efficacy of BAL5788, a Prodrug of Cephalosporin BAL9141, in a Mouse Model of Acute Pneumococcal Pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1105-1111

  Azoulay Dupuis, E ^a   Bedos J P ^a   Mohler, J ^a   Schmitt Hoffmann, A ^b   Schleimer, M ^b   Shapiro, S ^b  

^a INSERM   (France)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFOTAXIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; PENICILLIN G; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; LEUKOPENIA; LOBAR PNEUMONIA; LUNG; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; PROVOCATION TEST; STREPTOCOCCUS PNEUMONIAE; SURVIVAL;

ANIMALS; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; FEMALE; INJECTIONS, SUBCUTANEOUS; LEUKOPENIA; LUNG; MICE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; PRODRUGS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

EID: 1642543215     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1105-1111.2004     Document Type: Article

References (25)

1. Azoulay-Dupuis, E., E. Vallée, B. Veber, J. P. Bédos, J. Bauchet, and J. J. Pocidalo. 1992. In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob. Agents Chemother. 36:2698-2703.
2. Azoulay-Dupuis, E., V. Rieux, M. Muffat-Joly, J. P. Bédos, E. Vallée, C. Rivier, R. Isturiz, C. Carbon, and P. Moine. 2000. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob. Agents Chemother. 44:1575-1577.
3. Bartlett, J. G., and L. M. Mundy. 1995. Community-acquired pneumonia. N. Engl. J. Med. 333:1618-1624.
4. Boswell, T. C., K. J. Nye, and E. G. Smith. 1994. Penicillin- and penicillin-cephalosporin-resistant pneumococcal septicaemia. J. Antimicrob. Chemother. 34:844-845.
5. Bozdogan, B., D. Esel, C. Whitener, F A. Browne, and P. C. Appelbaum. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
6. Briles, D. E., M. J. Crain, B. M. Gray, C. Forman, and J. Yother. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect. Immun. 60:111-116.
7. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
8. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
9. Figueiredo, A. M. S., J. D. Connor, A. Severin, M. V. Vaz Pato, and A. Tomasz. 1992. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob. Agents Chemother. 36:886-889.
10. Goldstein, F. W., J. F. Acar, and The Alexander Project Collaborative Group. 1996. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A): 71-84.
11. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.
12. John, C. C. 1994. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and a review. Clin. Infect. Dis. 18:188-193.
13. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
14. Kuti, J. L., B. Capitano, and D. P. Nicolau. 2002. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 20:513-528.
15. Lieberman, D., F. Schlaeffer, I. Boldur, D. Lieberman, S. Horowitz, M. G. Friedman, M. Leiononen, O. Horovitz, E. Manor, and A. Porath. 1996. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 51:179-184.
16. McDougal, L. K., R. Facklam, M. Reeves, S. Hunter, J. M. Swenson, B. C. Hill, and F. C. Tenover. 1992. Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob. Agents Chemother. 36:2176-2184.
17. Moine, P., J. B. Vercken, S. Chevret, C. Chastang, P. Gajdos, and the French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. 1994. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. Chest 105:1487-1495.
18. Moine, P., E. Vallée, E. Azoulay-Dupuis, P. Bourget, J. P. Bédos, J. Bauchet, and J. J. Pocidalo. 1994. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 38:1953-1958.
19. Munoz, R., C. G. Dowson, M. Daniels, T. J. Coffey, C. Martin, R. Hakenbeck, and B. G. Spratt. 1992. Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol. Microbiol. 6:2461-2465.
20. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS publication M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 5th ed. NCCLS publication M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Oosterheert, J. J., M. J. M. Bonten, E. Hak, M. M. E. Schneider, and A. I. M. Hoepelman. 2003. Severe community-acquired pneumonia: what's in a name? Curr. Opin. Infect. Dis. 16:153-159.
23. Pallarés, R., J. Linarés, M. Vadillo, C. Cabellos, F. Manresa, P. F. Viladrich, R. Martin, and F. Gudiol. 1995. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 333:474-480. (Erratum, 333:1655.)
24. Sauve, C., E. Azoulay-Dupuis, P. Moine, C. Darras-Joly, V. Rieux, C. Carbon, and J. P. Bédos. 1996. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2829-2834.
25. Verhaegen, J., and L. Verbist. 1998. In-vitro activity of 21 β-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 41:381-385.